June 08, 2019 – For some time now, Tofacitinib (Xeljanz) receives intense attention in the media, with regulatory authorities, and patients and treating physicians alike because of serious concerns of increased risk of blood clots in the lungs and increased mortality in patients …

Tofacitinib (Xeljanz): Dangers of blood clots in the lungs and of death Read more »

September 30, 2017 – Obeticholic acid (Ocaliva) was approved by the American Food & Drug Administration (FDA) in May 2016 for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adult  patients with an inadequate response …

Obeticholic Acid (Ocaliva): Is there a serious drug safety problem? Read more »